# Junta clínica — PT-pseudo_2ef22b5dd08e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_2ef22b5dd08e",
  "pid": "PT-pseudo_2ef22b5dd08e",
  "task": 1,
  "psa": 9.3,
  "age": 66,
  "months": 2,
  "pirads": "4",
  "psad": 0.296,
  "psav": 1.34,
  "psap": 6.2,
  "vol": 31.46,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.8335312,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 9.3 ng/mL. PI-RADS 4. PSAD 0.30. Prostate volume 31 mL. csPCa 0.83.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "75 kg",
    "height": "184 cm",
    "bmi": "22.2",
    "bp": "136/76 mmHg",
    "hr": "71 bpm",
    "smoking": "Ex-smoker (24 pack-yr, quit 2020)",
    "last_dental": "6 mo ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "18 Feb 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical reassessment indicated due to a persistent upward PSA trajectory coupled with recent multiparametric magnetic resonance imaging results."
    },
    {
      "s": "History",
      "t": "At 66 years of age, this semi-retired harbour pilot seeks review concerning his prostate-specific antigen trajectory, accompanied by a longstanding record of moderate lower urinary tract symptoms (IPSS 8/35). He shares an assisted-living residence with his spouse, who serves as his main point of contact. Physical activity remains a priority, featuring three weekly cycling sessions covering roughly 30 km each, balanced with an alcohol intake of 8 units weekly. His smoking history totals 24 pack-years, though he ceased tobacco use in 2020. Ocular limitations necessitate large-print documents. Recent medical engagements include a gastroenterology visit for standard colonoscopy screening, pulmonary function testing, and a baseline chest radiograph. A laparoscopic gallbladder removal occurred in 2015, entirely separate from his present urological evaluation. He maintains no active comorbidities, takes no prescribed medications, manages occasional seasonal allergies with non-prescription antihistamines, and carries no prior biopsy history. No unexplained weight reduction, skeletal discomfort, or blood in the urine has been reported. General health otherwise appears stable."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: Normal DRE; digital assessment reveals a uniformly enlarged gland exhibiting consistent firmness without discrete irregularities or lateralised masses. Cardiovascular and respiratory auscultation demonstrate regular rhythms and clear field expansion. Abdominal percussion and palpation confirm a pliable, non-tender cavity lacking palpable hepatosplenomegaly or abnormal growths."
    }
  ],
  "occupation": "harbour pilot (semi-retired)",
  "marital": "Married",
  "living": "Lives in assisted-living facility",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Radiology — chest X-ray (routine)",
    "Pulmonary function test — known COPD follow-up"
  ],
  "alcohol": "8 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 8/35 (moderate LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2ef22b5dd08e
Task: 1

Encounter: Urology - outpatient on 18 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 9.3 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.296 ng/mL²
  - PSA velocity: 1.34 ng/mL/yr
  - Prior PSA: 6.2 ng/mL
  - Prostate volume: 31.46 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8335312 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 9.3 ng/mL. PI-RADS 4. PSAD 0.30. Prostate volume 31 mL. csPCa 0.83.

Vitals: weight 75 kg, height 184 cm, BMI 22.2, BP 136/76 mmHg, HR 71 bpm. Smoking: Ex-smoker (24 pack-yr, quit 2020).

Chief complaint: Clinical reassessment indicated due to a persistent upward PSA trajectory coupled with recent multiparametric magnetic resonance imaging results.

History: At 66 years of age, this semi-retired harbour pilot seeks review concerning his prostate-specific antigen trajectory, accompanied by a longstanding record of moderate lower urinary tract symptoms (IPSS 8/35). He shares an assisted-living residence with his spouse, who serves as his main point of contact. Physical activity remains a priority, featuring three weekly cycling sessions covering roughly 30 km each, balanced with an alcohol intake of 8 units weekly. His smoking history totals 24 pack-years, though he ceased tobacco use in 2020. Ocular limitations necessitate large-print documents. Recent medical engagements include a gastroenterology visit for standard colonoscopy screening, pulmonary function testing, and a baseline chest radiograph. A laparoscopic gallbladder removal occurred in 2015, entirely separate from his present urological evaluation. He maintains no active comorbidities, takes no prescribed medications, manages occasional seasonal allergies with non-prescription antihistamines, and carries no prior biopsy history. No unexplained weight reduction, skeletal discomfort, or blood in the urine has been reported. General health otherwise appears stable.

Physical examination: Per rectum: Normal DRE; digital assessment reveals a uniformly enlarged gland exhibiting consistent firmness without discrete irregularities or lateralised masses. Cardiovascular and respiratory auscultation demonstrate regular rhythms and clear field expansion. Abdominal percussion and palpation confirm a pliable, non-tender cavity lacking palpable hepatosplenomegaly or abnormal growths.

Patient info: harbour pilot (semi-retired); Married; Lives in assisted-living facility.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 8 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 8/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Radiology — chest X-ray (routine); Pulmonary function test — known COPD follow-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.93
  uncertainty  +/- 0.04 (95% CI 0.86-1.00); among patients it cannot tell apart the outcome was 0.37 of 1.00 mixed
  confidence   HIGH — in this tier it was right in every one of the 28 labelled cases it covered

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests using a PI-RADS threshold of $\ge 3$ to trigger a biopsy. The retrieved text states, "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]." This requires the conference to establish if this threshold applies to this patient given the context.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently grounded in the guideline because it appears to ignore the context of the PI-RADS score and the patient's prior biopsy status. The guideline provides a threshold ($\ge 3$), but the classifier's bid does not account for the specific risk stratification provided by the MRI, which is a variable the guideline makes decisive.

WHAT WE STILL NEED
The mpMRI prose - the mpMRI prose does not compare against an earlier study, so the guideline does not dictate a specific action based on stability.
Prior biopsy status - the patient has "None," which is a variable the guideline makes decisive, as the guideline mentions the impact of being biopsy-naïve.
PSA trend - the PSA velocity is $1.34 \text{ ng/mL/yr}$, which is a variable the guideline makes decisive, as the guideline discusses risk stratification based on PSA density.
Prostate volume - the prostate volume is $31.46 \text{ mL}$, which is a variable the guideline makes decisive, as the guideline mentions that PSA-D is a significant predictor.
The mpMRI prose - the mpMRI prose does not compare against an earlier study, so the guideline does not dictate a specific action based on stability.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the PI-RADS 4 score in a biopsy-naïve patient warrants proceeding to biopsy, given the guideline's context regarding prior biopsy status and PSA velocity.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Establish the mpMRI prose, specifically whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine the context of the PSA velocity of 1.34 ng/mL/yr.
  previous_notes (get_previous_notes) -> Clarify the management context, specifically regarding the decision pathway for biopsy in this scenario.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the significance of the PSA velocity of 1.34 ng/mL/yr in determining the management pathway?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Does the PI-RADS 4 score, in the context of a biopsy-naïve patient, meet the threshold for biopsy according to the EAU guideline?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose states that the lesion is not compared against an earlier study.
psa_trend
The PSA velocity is $1.34 \text{ ng/mL/yr}$, with a value of $9.3 \text{ ng/mL}$ in February 2025, following a previous value of $6.2 \text{ ng/mL}$ in April 2024.
previous_notes
The previous notes clarify that the GP was tracking PSA levels, with a measurement of $6.2 \text{ ng/mL}$ in April 2024, and a previous visit in March 2023 with a level of $8.7 \text{ ng/mL}$.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not specifically ask for them, and the key information regarding PSA density was already present in the panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
The EXPERT-COHORT criterion matched the reading urologist in 24 of 24 cases when the mpMRI showed a PI-RADS 3 or higher lesion.
The EXPERT-CLASSIFIER suggested biopsy with a high probability of correctness in the covered tier.
AGAINST sampling this patient now
The EXPERT-EAU noted that the guideline requires establishing if the PI-RADS 4 score applies given the context.

WHERE THIS LEANS
The data suggests a strong inclination towards biopsy based on the PI-RADS 4 score and the patient being biopsy-naïve, which aligns with the cohort data.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened have partially answered the moderator's questions; the `radiology_report` confirmed the lesion is not compared against an earlier study, and `psa_trend` provided the velocity.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of biopsy, as the cohort criterion matched the reading urologist in 24 of 24 cases for PI-RADS $\ge 3$ lesions, and the registrar noted the strong inclination towards biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the significance of the PSA velocity of 1.34 ng/mL/yr in determining the management pathway? This is answered by the `psa_trend` which provides the velocity, but the documents do not explicitly state the guideline's interpretation of this velocity for management.

WHAT CARRIES WEIGHT, AND WHY
The relevant variables are the PI-RADS 4 score because it is the primary driver for the cohort criterion, the prior biopsy status because the guideline explicitly mentions the impact of being biopsy-naïve, and the PSA velocity because the guideline discusses risk stratification based on PSA density. The guideline does not explicitly support the leaning towards biopsy over deferral based on the current data.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the PI-RADS 4 score in a biopsy-naïve patient strongly aligns with the cohort data, despite the guideline requiring further context on the PSA velocity.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

The PI-RADS 4 score is decisive, and the patient is biopsy-naïve, which strongly aligns with the cohort data suggesting biopsy. The PSA velocity of 1.34 ng/mL/yr and the PSA density of 0.296 ng/mL^2 further support proceeding with a biopsy. The room converged on the decision to sample given the high-risk imaging finding and lack of prior pathology.

What carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive
Documents this conference opened: radiology_report, psa_trend, previous_notes
